Intravacc and Primrose Bio Announce Partnership to Enhance Conjugate Vaccine Development
The companies will leverage their combined experience in the development of conjugate vaccines for their clients
- Primrose Bio will supply its industry-leading carrier protein, PeliCRM197®, for vaccine development
- Intravacc has IP and know how in vaccine conjugation and manufacturing of carrier protein based products
- Clients active in conjugate vaccines will benefit from a seamless solution across development and manufacturing
Bilthoven, The Netherlands, 26 march 2024 – Intravacc, a leading global contract development and manufacturing organization (CDMO) specializing in infectious disease and therapeutic vaccines, and Primrose Bio, a biotechnology company with leading technologies that improve the manufacturing of next-generation therapeutics, announced a strategic partnership to enhance the development and supply of conjugate vaccines. Third parties engaged in developing conjugate vaccines will have access to a seamless solution for vaccine conjugation, manufacturing and supply.
Dr. Jan Groen, Intravacc’s CEO, says:
“We are excited to announce our partnership with Primrose Bio. By combining our expertise with Primrose's cutting-edge technologies, we aim to revolutionize the landscape of conjugate vaccine development, ultimately benefiting millions worldwide."
Dr. Helge Zieler, Primrose Bio’s CEO, further comments:
“Expanding the capability of our PeliCRM197® franchise with Intravacc now creates a full-service solution for our early-stage customers and partners needing vaccine conjugation development. With both companies having direct product experience in preclinical, manufacturing, and clinical development, the combined know-how of the two firms fills a gap that is needed by the vaccine industry as a whole.”
This partnership harnesses the synergistic strengths of both companies, fostering innovation and efficiency in vaccine development. Intravacc contributes its comprehensive technical expertise, state-of-the-art facilities, and robust capabilities in antigen conjugation process development, scale-up, and GMP production of conjugate vaccines. Primrose Bio complements this with its ultra-pure production, supply chain, and regulatory support for the PeliCRM197® carrier protein, a vital ingredient in conjugate vaccine formulations and the only commercial CRM197 used in commercial vaccines available for purchase. This carrier protein is offered in a range of quantities and grades, from milligrams to kilograms, both for research and GMP applications. The partnership signifies a strategic alignment aimed at advancing vaccine development and accessibility for researchers and industry clients.
